Imunon, Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M |
| SG&A Expense | $13.7M | $10.9M | $7.6M | $8.0M | $9.7M | $5.9M |
| Operating Income | $-24.9M | $-21.0M | $-18.5M | $-20.6M | $-21.1M | $-18.5M |
| Operating Margin | -4,984.3% | -4,201.4% | -3,697.3% | -4,113.1% | -4,213.0% | -3,693.7% |
| Interest Expense | $5.0M | $569.9K | $1.3M | — | — | — |
| Pretax Income | $-37.5M | $-22.2M | $-23.3M | $-18.7M | $-22.3M | $-20.4M |
| Income Tax Expense | $-1.6M | $-1.4M | $-1.8M | $-1.8M | $-10.4M | — |
| Net Income | $-35.9M | $-20.8M | $-21.5M | $-16.9M | $-11.9M | $-20.4M |
| Net Margin | -7,179.6% | -4,153.9% | -4,296.7% | -3,370.3% | -2,376.7% | -4,080.4% |
| EPS (Basic) | $-5.03 | $-3.83 | $-10.08 | $-0.77 | $-0.68 | $-2.72 |
| EPS (Diluted) | $-5.03 | $-3.83 | $-10.08 | $-0.77 | $-0.68 | $-2.72 |
| Shares Outstanding (Basic) | 7.1M | 5.4M | 2.7M | 23.3M | 18.8M | 17.3M |
| Shares Outstanding (Diluted) | 7.1M | 5.4M | 2.7M | 23.3M | 18.8M | 17.3M |
| Dividends Per Share | — | — | — | — | — | — |